Society on Sarcopenia, Cachexia and Wasting Disorders

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is an international and multidisciplinary non-profit organization, created in 2008.[1] It focuses on Cachexia[2] and Sarcopenia.

Cachexia and sarcopenia are a major public health problem: frequent, costly, and deadly.[3] They are often under-diagnosed and patients groups try to improve awareness about them.[4] Cachexia has been coined as the "last illness"[5] and is sometime called "body wasting". The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer.[6] It is estimated that 5 Million Americans have the condition and Cachexia is frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis.[7] Mortality rates of patients with cachexia range from 15–25% per year in severe COPD through 20–40% per year in patients with chronic heart failure or chronic kidney disease to 20–80% in cancer cachexia.[8] SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker,[9] Germany and Dr. John E. Morley,[10] USA. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting.[11] As of 2018, the society had 150 members.

The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) are to:

  • To improve the understanding, diagnosis and treatment of skeletal muscle wasting in various disease conditions and aging[12]
  • Educate healthcare professionals
  • Form partnerships with other professional societies[13]

The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization (501 c3)[14] registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology,[15] the Vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage.[16]
The Board is made up of :
Stefan D. Anker (President[17]) – Berlin, Germany
Josep M. Argiles – Barcelona, Spain
Vickie E. Baracos – Edmonton, Canada
Andrew J. S. Coats (Treasurer) – Norwich, UK
Wolfram Doehner – Berlin, Germany
William J. Evans[18] – Duke University, USA
Luigi Ferrucci[19] – Baltimore, USA
David J. Glass – Boston, USA
Akio Inui – Kobe, Japan
Aminah Jatoi – Rochester, USA
Kamyar Kalantar-Zadeh – Los Angeles, USA
John E. Morley (Vice-president) – St. Louis, USA
Filippo Rossi-Fanelli – Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany

Prof Ken Fearon was a Board member until he passed away in September 2016.[20] He had received the Hippocrates Award from the Society.[21] Professor Fearon was particularly involved in cancer cachexia: leading an international consensus.[22]

Educational initiatives

Conferences

Since 2000[23] the SCWD Society has organized several international conferences.[24] In 2009, the conference[25] took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy.[26] One of them took place in Kobe,[27] Japan. Those conferences have taken place every two years. However, in 2015, in Paris,[28] it was decided to organize the conferences annually.[29] The location of the 2016 congress is Berlin on 10–11 December 2016.[30] The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting.[31]

It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing.[32] Update on Anabolics and Related Therapie sare also provided.[33] Results of clinical trials are also presented, such as data from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013.[34] The latest conference took place in Maastricht in 2018. In 2019, the international conference will take place in Berlin.


Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.

Attendance:[35]

YearCongressVenueNo of Registered Delegates
20001stBerlin150
20032ndBerlin250
20053rdRome300
20074thTampa340
20095thBarcelona410
20116thMilano450
20137thKobe390
20158thParis500
2016 9th Berlin 300
2017 10th Rome 470
2018 11th Maastricht
2019 12th Berlin


A charity dinner is sometimes organised during SCWD Conférences such as in 2011 in Milan with the participation of Lisa Niemi.[36]

Posters: each meeting features 120-200 posters.[37]

The SCWD releases regular highlights of its meetings.[38]

Consensus meetings

Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia[39] as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting.[40]
The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements[41] based on the following topics:

  • Definitions of Cachexia, Sarcopenia[42] and Frailty with a proposal for an overall disease classification system of "Muscle Wasting Syndromes" as frame-work of reference.
  • Classification.[43]
  • Body composition assessment.
  • End-points in clinical trials including Patient-reported outcomes.
  • Nutrition.[44]
  • Endpoint in clinical trials: strengths and weaknesses.
  • What constitutes clinically meaningful change.
  • New regulatory pathways.

These consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues.
These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia[45] They also generated recommendations for nutritional management.[46]

Journal

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) published by Wiley-Blackwell is the official journal of SCWD.[47] It was created in 2010.[48] According to the Journal Citation Reports, the journal has a 2017 impact factor of 12.511. JCSM has seen an increase in citations and submissions in 2016.[49] It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal.[50] Two daughter journals also exist: JCSM—Clinical Reports started in July 2016 and JCSM—Rapid Communications.

About Muscle Wasting, Cachexia and Sarcopenia

Cachexia is a major issue, especially in the elderly.[51] Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.[52] Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity / mortality. Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia.[53] Sarcopenia and cachexia represent the major causes of muscle-wasting disorders. It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.
It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.[54]
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness[55] that lead to increased morbidity and mortality.[56] The cost of muscle wasting is high.[57]

References
  1. "Come Together to support a cause that matters to you!". Retrieved 2016-12-07.
  2. What is cancer cachexia
  3. Farkas, Jerneja; von Haehling, Stephan; Kalantar-Zadeh, Kamyar; Morley, John E.; Anker, Stefan D.; Lainscak, Mitja (2016-12-07). "Cachexia as a major public health problem: frequent, costly, and deadly". Journal of Cachexia, Sarcopenia and Muscle. 4 (3): 173–178. doi:10.1007/s13539-013-0105-y. ISSN 2190-5991. PMC 3774921. PMID 23539127.
  4. McDaniels, Andrea K. "Groups seek better diagnosis and treatment of debilitating muscle loss in seniors". baltimoresun.com. Retrieved 2018-02-09.
  5. Lok, Corie (2015-12-10). "Cachexia: The last illness". Nature. 528 (7581): 182–183. Bibcode:2015Natur.528..182L. doi:10.1038/528182a. PMID 26659165. S2CID 4469244.
  7. "Cachexia: Symptoms, Treatment, and Outlook". Medical News Today. Retrieved 2017-01-24.
  8. von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (2016-12-01). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  9. "Curriculum vitae" (PDF).
  10. "One of the nation' foremost authorities on geriatrics". Saint Louis University.
  11. "The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA". Newswire.
  12. "Society on sarcopenia, cachexia and wasting disorders". research.longfonds.nl. Retrieved 2016-12-07.
  13. "Journal of Cachexia, Sarcopenia and Muscle - Society Information -". Wiley Online Library. doi:10.1007/13539.2190-6009/homepage/Society (inactive 2021-01-10). Cite journal requires |journal= (help)CS1 maint: DOI inactive as of January 2021 (link)
  15. "ESC Board". www.escardio.org. Retrieved 2016-12-07.
  16. Coats, Andrew JS (2002). "Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath". International Journal of Cardiology. 85 (1): 133–139. doi:10.1016/s0167-5273(02)00242-5. PMID 12163218.
  17. "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 2017-09-27. Retrieved 2018-02-09.
  18. "Regulatory Recognition Key to Moving Forward on Sarcopenia: Interview with Dr. Bill Evans, GSK". 2012-09-13.
  20. "editorial". Clinical Nutrition.
  21. "Obituary - Kenneth Fearon, professor of surgical oncology". HeraldScotland. Retrieved 2016-12-07.
  22. Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (2011-05-01). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN 1474-5488. PMID 21296615.
  23. Anker, Markus S.; von Haehling, Stephan; Springer, Jochen; Banach, Maciej; Anker, Stefan D. (2013-02-21). "Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology". Archives of Medical Science. 9 (1): 166–171. doi:10.5114/aoms.2013.33356. ISSN 1734-1922. PMC 3598129. PMID 23515589.
  24. "Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 43–128. 2010-09-01. doi:10.1007/s13539-010-0001-7. ISSN 2190-6009. PMC 3060650. PMID 22477519.
  25. (PDF) http://medschool.slu.edu/uploads/images/5th_Cachexia_Conference_2009.pdf. Missing or empty |title= (help)
  26. "Elderly Women Prefer Death to Suffering a Hip Fracture". 2014-06-11.
  27. "Congress Report - 7th Cachexia Conference Kobe/Osaka, Japan, December 9−11, 2013 | Literature watch | Cancer Cachexia".
  29. von Haehling, S; Anker, SD (2016-02-22). "The times they are a‐changin': the Cachexia Conference goes annual". Journal of Cachexia, Sarcopenia and Muscle. 7 (1): 3–4. doi:10.1002/jcsm.12110. PMC 4771211. PMID 27066313.
  30. cancercachexia2016 http://cancercachexia2016.com/html/events.html. Missing or empty |title= (help)
  31. "SINU – Società Italiana di Nutrizione Umana" (PDF).
  32. von Haehling, Stephan; Anker, Stefan D. (2010-09-01). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. ISSN 2190-6009. PMC 3060651. PMID 21475699.
  33. Group, Helsinn. "Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/". www.prnewswire.co.uk. Retrieved 2016-12-08.
  34. "Lundbeckfond Ventures ' MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING". www.lundbeckfonden.com. Retrieved 2016-12-12.
  35. Haehling, Stephan von; Anker, Stefan D. (2011-11-09). "The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area". Journal of Cachexia, Sarcopenia and Muscle. 2 (4): 189–190. doi:10.1007/s13539-011-0048-0. ISSN 2190-5991. PMC 3222803. PMID 22207906.
  36. "6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner". www.newswire.com. Retrieved 2016-12-07.
  37. "Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 51–68. 2012-01-31. doi:10.1007/s13539-012-0056-8. ISSN 2190-5991. PMC 3302985. PMID 22460563.
  38. Ebner, Nicole; Werner, Claudia G.; Doehner, Wolfram; Anker, Stefan D.; Haehling, Stephan von (2012-03-02). "Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 45–50. doi:10.1007/s13539-012-0061-y. ISSN 2190-5991. PMC 3302986. PMID 22460618.
  39. Morley, John E.; Abbatecola, Angela Marie; Argiles, Josep M.; Baracos, Vickie; Bauer, Juergen; Bhasin, Shalender; Cederholm, Tommy; Coats, Andrew J. Stewart; Cummings, Steven R. (2011-07-01). "Sarcopenia with limited mobility: an international consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. ISSN 1538-9375. PMC 5100674. PMID 21640657.
  40. Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (2008-12-01). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN 1532-1983. PMID 18718696.
  41. Advances in Food and Nutrition Research. Academic Press. 2014-01-30. ISBN 9780128003688.
  42. morley, john (2011). "Sarcopenia With Limited Mobility: An International Consensus". Jamda. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. PMC 5100674. PMID 21640657.
  43. Argilés, Josep M.; López-Soriano, Francisco J.; Toledo, Míriam; Betancourt, Angelica; Serpe, Roberto; Busquets, Sílvia (2016-12-08). "The cachexia score (CASCO): a new tool for staging cachectic cancer patients". Journal of Cachexia, Sarcopenia and Muscle. 2 (2): 87–93. doi:10.1007/s13539-011-0027-5. ISSN 2190-5991. PMC 3117995. PMID 21766054.
  44. Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (2010-07-01). "Nutritional recommendations for the management of sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN 1538-9375. PMC 4623318. PMID 20627179.
  45. Definition of Sarcopenia
  46. Watson, Ronald Ross; Preedy, Victor R. (2013-01-01). Bioactive Food as Dietary Interventions for the Aging Population. Academic Press. ISBN 9780123971555.
  47. Wiley-Blackwell online library
  48. von Haehling, Stephan; Anker, Stefan D. (2018-11-18). "Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018". Journal of Cachexia, Sarcopenia and Muscle. 9 (6): 1021–1022. doi:10.1002/jcsm.12366. ISSN 2190-5991. PMC 6240749. PMID 30450844.
  49. Journal of Cachexia, Sarcopenia and muscle
  50. von Haehling, Stephan; Anker, Stefan D. (2015-09-01). "Moving on up: the Journal of Cachexia, Sarcopenia and Muscle". Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 193–196. doi:10.1002/jcsm.12064. ISSN 2190-6009. PMC 4575549. PMID 26401464.
  51. Mantovani, Giovanni (2006). Cachexia and Wasting: A Modern Approach. Milan: Springer. ISBN 978-8847004719.
  52. Anker, Stefan D.; Morley, John E (2015-12-01). "Cachexia: a nutritional syndrome?". Journal of Cachexia, Sarcopenia and Muscle. 6 (4): 269–271. doi:10.1002/jcsm.12088. ISSN 2190-6009. PMC 4670732. PMID 26675043.
  53. Evans, William J. (2010-04-01). "Skeletal muscle loss: cachexia, sarcopenia, and inactivity". The American Journal of Clinical Nutrition. 91 (4): 1123S–1127S. doi:10.3945/ajcn.2010.28608A. ISSN 0002-9165. PMID 20164314.
  54. Morley, John E. (2016-09-26). "Frailty and sarcopenia in elderly". Wiener Klinische Wochenschrift. 128 (Suppl 7): 439–445. doi:10.1007/s00508-016-1087-5. ISSN 1613-7671. PMID 27670855. S2CID 20112072.
  55. "Patients Suffering From Cachexia Need Nutritional Support". Cure Today. Retrieved 2018-02-09.
  56. von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (2016-12-01). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  57. Author, Brent Green; Boomers", "Marketing to Leading-Edge Baby; Reinvention, "Generation; Speaker, "; Host, Radio (2011-12-06). "Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity". The Huffington Post. Retrieved 2016-12-07.CS1 maint: numeric names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.